--- title: "Daiwa Capital Markets: AI innovation and national policies drive the mainland internet healthcare sector, optimistic about ALI HEALTH and PA GOODDOCTOR" description: "Daiwa Capital Markets' research report points out that the mainland internet healthcare sector is entering a new stage, driven by innovations in AI from tech giants and support from national policies." type: "news" locale: "en" url: "https://longbridge.com/en/news/275842014.md" published_at: "2026-02-13T02:21:54.000Z" --- # Daiwa Capital Markets: AI innovation and national policies drive the mainland internet healthcare sector, optimistic about ALI HEALTH and PA GOODDOCTOR > Daiwa Capital Markets' research report points out that the mainland internet healthcare sector is entering a new stage, driven by innovations in AI from tech giants and support from national policies. Despite facing profitability challenges, leading companies are leveraging the AI ecosystem to achieve long-term growth. The firm is optimistic about ALI HEALTH and PA GOODDOCTOR, maintaining a "Buy" rating with target prices of 7.8 yuan and 20 yuan, respectively. It is expected that ALI HEALTH's revenue and net profit compound annual growth rates for the fiscal years 2026 to 2028 will be 13% and 24%; PA GOODDOCTOR's revenue and net profit compound annual growth rates for 2025 to 2027 will be 16% and 56% Daiwa Capital Markets' research report indicates that the mainland internet healthcare sector is entering a new phase, driven by factors such as technology giants accelerating AI innovation and national policy support, such as the online initial diagnosis pilot program launched in Beijing. Although facing challenges in profitability, leading companies are leveraging the AI ecosystem and innovative strategies to deploy long-term sustainable growth. In terms of stock selection, the firm is optimistic about ALI HEALTH (00241.HK), maintaining a "Buy" rating and a target price of HKD 7.8; it is expected that under the continued growth momentum of innovative drugs and healthcare products, the deepening synergy with Alibaba (09988.HK), and the increasing prevalence of AI applications, ALI HEALTH's revenue and adjusted net profit compound annual growth rates for the fiscal years 2026 to 2028 will reach 13% and 24%, respectively. Additionally, the firm is also optimistic about PA GOODDOCTOR (01833.HK), maintaining a "Buy" rating with a target price of HKD 20; it is expected that under the deepening synergy with China Ping An (02318.HK) and the ongoing empowerment of AI, the company's revenue and adjusted net profit compound annual growth rates for the years 2025 to 2027 will reach 16% and 56%, respectively. At the same time, the firm maintains an "Overweight" rating for the mainland healthcare sector, preferring leading innovative pharmaceutical companies and contract research, development, and manufacturing organizations (CRDMOs), while also favoring internet healthcare companies that can effectively utilize real-world data to optimize AI algorithms to enhance service quality. Preferred stocks include BeiGene (06160.HK), Innovent Biologics (01801.HK), Hansoh Pharmaceutical (03692.HK), China National Pharmaceutical Group (01177.HK), Hutchison China MediTech (00013.HK), WuXi Biologics (02269.HK), WuXi AppTec (02359.HK), and ALI HEALTH. Daiwa Capital Markets' investment ratings and target prices for pharmaceutical stocks are listed as follows: Stock | Investment Rating | Target Price (HKD) Hutchison China MediTech (00013.HK) | Buy | 32.5 Stone Group Holdings (01093.HK) | Hold | 8.5 China National Pharmaceutical Group (01099.HK) | Hold | 20 China Biologic Products (01177.HK) | Buy | 10.5 Innovent Biologics (01801.HK) | Buy | 130 PA GOODDOCTOR (01833.HK) | Buy | 20 WuXi Biologics (02269.HK) | Buy | 52 WuXi AppTec (02359.HK) | Buy | 152 ALI HEALTH (00241.HK) | Buy | 7.8 Shenwei Pharmaceutical (02877.HK) | Hold | 8.5 Hansoh Pharmaceutical (03692.HK) | Buy | 50 Fosun Pharma (03933.HK) | Buy | 20 Yuan BeiGene (06160.HK) | Buy | 252 Yuan ### Related Stocks - [00241.HK - ALI HEALTH](https://longbridge.com/en/quote/00241.HK.md) - [01833.HK - PA GOODDOCTOR](https://longbridge.com/en/quote/01833.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 紅包大戰，阿里 (9988) 千問 App 斥 30 億發起攻勢推春節請客計劃 | 阿里巴巴旗下千問 App 宣佈投入 30 億元啟動「春節請客計劃」，該計劃將於 2 月 6 日正式上線。春節期間，千問 App 將與阿里生態業務如淘寶閃購、飛豬等合作，以免單形式邀請全國民眾參與，推動春節期間的消費和體驗，開啟 AI 時代的 | [Link](https://longbridge.com/en/news/274612856.md) | | 科網股跌咗落嚟博乜好｜唐牛 | 港股因金銀價格波動及電訊商税收變化而劇烈波動，恆指從 28 樓跌至 26 樓。科技股受增值税上調傳聞影響，騰訊股價大跌，指數由升 300 點轉為跌 300 點。儘管傳聞被澄清，市場情緒仍然緊張。建議關注阿里和百度的低位買入機會，因其有晶片分 | [Link](https://longbridge.com/en/news/274736956.md) | | 研究表明，人工智能可以將利潤率提高最多 1.9%，因為 Ever.Ag 正在推進農業零售領域的嵌入式智能技術 | Ever.Ag 宣佈在其農業零售解決方案 Merchant Ag 中推進人工智能集成，旨在提升農業零售商的運營效率。這一方法通過將智能嵌入現有工作流程，解決了勞動力限制和供應鏈中斷等挑戰。研究表明，應用人工智能可以將利潤率提高 1.2% 至 | [Link](https://longbridge.com/en/news/276251123.md) | | 阿里創業者基金 CEO 指 AI 無明顯泡沫 市場投資邏輯轉向兼顧 AI 治理與責任應用 | 阿里巴巴創業者基金 CEO 周駱美琪表示，當前 AI 市場無明顯泡沫，投資邏輯已轉向兼顧 AI 治理與責任應用。與 2000 年網際網路泡沫不同，當前 AI 企業估值與業績匹配度較高。她分析中美 AI 賽道機遇各有側重，基金重點佈局算力賦能 | [Link](https://longbridge.com/en/news/274798140.md) | | 股價還能再漲 55%！英國對沖基金押注：全球最大馬桶製造商 TOTO 將是 AI 芯片隱形贏家 | 馬桶巨頭變身 AI 概念股！激進投資者 Palliser 盯上日本 TOTO，稱其為” 最被低估的 AI 受益者”。這家衞浴製造商憑陶瓷技術掌握半導體核心設備靜電卡盤，貢獻 40% 運營利潤，股價一年已漲超 60%。Palliser 測算仍 | [Link](https://longbridge.com/en/news/276110046.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.